Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2017

GlobalData
48 Pages - GLDATA63012
$2,500.00

Summary

GlobalData's clinical trial report, “Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2017" provides an overview of Lymphangioleiomyomatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Lymphangioleiomyomatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Novartis AG
Pfizer Inc
Tuberous Sclerosis Alliance
Nobelpharma Co Ltd
MultiMedica SpA
LAM Therapeutics
C. H. Boehringer Sohn AG & Co KG
AstraZeneca Plc

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
GlobalData Clinical Trials Report Coverage 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Lymphangioleiomyomatosis to Respiratory Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Lymphangioleiomyomatosis to Respiratory Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Lymphangioleiomyomatosis Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profile Snapshots 27
Appendix 46
Abbreviations 46
Definitions 46
Research Methodology 47
Secondary Research 47
About GlobalData 48
Contact Us 48
Source 48

List of Tables
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials by Region, 2017* 6
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 9
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
Lymphangioleiomyomatosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 12
Proportion of Lymphangioleiomyomatosis to Respiratory Clinical Trials, G7 Countries (%), 2017* 13
Lymphangioleiomyomatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
Lymphangioleiomyomatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
Proportion of Lymphangioleiomyomatosis to Respiratory Clinical Trials, E7 Countries (%), 2017* 16
Lymphangioleiomyomatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials by Phase, 2017* 18
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 19
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 20
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 21
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 22
Lymphangioleiomyomatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 23
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 24
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 25
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 26

List of Figures
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 9
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
Lymphangioleiomyomatosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 11
Proportion of Lymphangioleiomyomatosis to Respiratory Clinical Trials, G7 Countries (%), 2017* 13
Lymphangioleiomyomatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
Lymphangioleiomyomatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
Proportion of Lymphangioleiomyomatosis to Respiratory Clinical Trials, E7 Countries (%), 2017* 16
Lymphangioleiomyomatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 18
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 19
Lymphangioleiomyomatosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 20
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 21
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 22
Lymphangioleiomyomatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 23
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 24
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 25
Lymphangioleiomyomatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 26
GlobalData Methodology 47

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports